Antagonizing CCR2 with propagermanium promotes alternative macrophage activation, improving cardiac remodeling and function after myocardial infarction in mice.
Antagonizing CCR2 with propagermanium in a mouse model of myocardial infarction improves cardiac remodeling and function by promoting alternative macrophage activation.
Absolute Event Rate: 0% vs 0%
Our results suggest that altering the activation type and distribution of invading macrophages in favor of alternative activation improves cardiac remodeling and function following MI.
Weipert et al. (Wed,) reported a other. Antagonizing CCR2 with propagermanium promotes alternative macrophage activation, improving cardiac remodeling and function after myocardial infarction in mice.